# US 2015/0147355 A1 · Compositions and Methods of Vaccination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147355 A1
- Document ID: US20150147355A1
- Status: Published application
- Kind: A1
- Application number: 14/401,795
- Filed: 2013-03-08
- Published: 2015-05-28
- Earliest claimed: 2012-05-17
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Akiko Iwasaki; Norifuma Iijima; Haina Shin
- Web page: https://patentgrep.com/patent/US20150147355A1

## CPC

- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/541: {Mucosal route}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- C12N 2710/16634: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a vaccination strategy that establishes protective immunity, including a protective memory T-cell population.

## Claims

### Claim 1

A method of inducing an immune response in a subject in need thereof, and recruiting the immune response to an anatomic location of the subject, comprising the steps of:
a. parenterally administering to the subject at least one immunogen, wherein the at least one immunogen induces an immune response; and
b. locally administering to the anatomic location of the subject at least one chemokine, wherein the chemokine recruits the immune response to the anatomic location.

### Claim 2 (depends on 1)

The method of claim 1, wherein the parenteral administration of the at least one immunogen is at least one selected from the group consisting of subcutaneous administration, intravenous administration, intramuscular administration, and intradermal administration.

### Claim 3 (depends on 1)

The method of claim 1, wherein the local administration of the at least one chemokine is at least one selected from the group consisting of topical administration, subcutaneous administration, intramuscular administration, intradermal administration, intracranial administration and intratumoral administration.

### Claim 4 (depends on 1)

The method of claim 1, wherein the chemokine is at least one selected from the group consisting of CXCL9, CXCL10 and CCL5.

### Claim 5 (depends on 1)

The method of claim 1, wherein the anatomic location is an immunologically restrictive tissue.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anatomic location is at least one selected from the group consisting of the genital mucosa, a tumor, the skin, the central nervous system, the peripheral nervous system, the testes, the placenta, the eye, the intestine, and the lung airways.

### Claim 7 (depends on 1)

The method of claim 1, wherein the immunogen is derived from a cancer cell.

### Claim 8 (depends on 1)

The method of claim 1, wherein the immunogen is a derived from a tumor.

### Claim 9 (depends on 1)

The method of claim 1, wherein the immunogen is derived from a pathogen selected from the group consisting of a virus, a bacterium, a fungi and a protozoan.

### Claim 10 (depends on 1)

The method of claim 1, wherein the immunogen is at least one component of at least one selected from the group consisting of a live pathogenic organism, a live attenuated pathogenic organism, an inactivated pathogenic organism, and a dead pathogenic organism.

### Claim 11 (depends on 1)

The method of claim 1, wherein the immunogen is at least one selected from the group consisting of a peptide, a polypeptide, and a polynucleotide encoding a polypeptide.

### Claim 12 (depends on 11)

The method of claim 11, wherein the polynucleotide encoding a polypeptide is at least one selected from RNA and DNA.

### Claim 13 (depends on 11)

The method of claim 11, wherein the polynucleotide encoding a polypeptide is a DNA vaccine.

### Claim 14 (depends on 9)

The method of claim 9, wherein the subject is not currently infected with the pathogen and the immune response is a protective immune response.

### Claim 15 (depends on 9)

The method of claim 9, wherein the subject is currently infected with the pathogen and the immune response is a therapeutic immune response.

### Claim 16 (depends on 7)

The method of claim 7, wherein the subject does not currently have cancer and the immune response is a protective immune response.

### Claim 17 (depends on 7)

The method of claim 7, wherein the subject currently has cancer and the immune response is a protective immune response.

### Claim 18 (depends on 1)

The method of claim 1, wherein the immune response comprises a humoral immune response.

### Claim 19 (depends on 1)

The method of claim 1, wherein the immune response comprises at least one antibody.

### Claim 20 (depends on 1)

The method of claim 1, wherein the immune response comprises at least one antibody that specifically binds to the immunogen.

### Claim 21 (depends on 1)

The method of claim 1, wherein the immune response comprises a cell-mediated immune response.

### Claim 22 (depends on 1)

The method of claim 1, wherein the immune response comprises at least one activated immune cell.

### Claim 23 (depends on 1)

The method of claim 1, wherein the activated immune cell is a CD4+ T cell.

### Claim 24 (depends on 1)

The method of claim 1, wherein the activated immune cell is a CD8+ T cell.

### Claim 25 (depends on 1)

The method of claim 1, wherein the activated immune cell is a CXCR3+ T cell.

### Claim 26 (depends on 1)

The method of claim 1, wherein the activated immune cell is a CXCR3+CD4+ T cell.

### Claim 27 (depends on 1)

The method of claim 1, wherein the activated immune cell is a CXCR3+CD8+ T cell.

### Claim 28 (depends on 1)

The method of claim 1, wherein the activated immune cell is a CCR5+ T cell.

### Claim 29 (depends on 1)

The method of claim 1, wherein the activated immune cell is a CCR5+CD4+ T cell.

### Claim 30 (depends on 1)

The method of claim 1, wherein the activated immune cell is a CCR5+CD8+ T cell.

### Claim 31 (depends on 1)

The method of claim 1, wherein the subject is human.
